Investigational new drug applications and new drug applications--FDA. Final rule.
The Food and Drug Administration (FDA) is amending its regulations pertaining to new drug applications (NDA's) to clearly define in the NDA format and content regulations the requirement to present effectiveness and safety data for important demographic subgroups, specifically gender, age, and racial subgroups. FDA also is amending its regulations pertaining to investigational new drug applications (IND's) to require sponsors to tabulate in their annual reports the numbers of subjects enrolled to date in clinical studies for drug and biological products according to age group, gender, and race. This action is intended to alert sponsors as early as possible to potential demographic deficiencies in enrollment that could lead to avoidable deficiencies later in the NDA submission. This rule does not address the requirements for the conduct of clinical studies and does not require sponsors to conduct additional studies or collect additional data. It also does not require the inclusion of a particular number of individuals from specific subgroups in any study or overall. The rule refers only to the presentation of data already collected.
D000367:Age Factors; D003625:Data Collection / Q000592:standards; D017277:Drug Approval / Q000331:legislation & jurisprudence; D005006:Ethnicity; D005260:Female; D006801:Humans; D017387:Investigational New Drug Application / Q000331:legislation & jurisprudence*; D008297:Male; D014481:United States; D014486:United States Food and Drug Administration